PER-082-06已完成未知
ong-term safety extension study during treatment with tocilizumab (MRA) in patients who have completed the MRA treatment of the central studies
PRODUCTOS ROCHE Q.F.S.A.,0 个研究点目标入组 34 人开始时间: 2006年10月20日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 34
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 0（—）
入选标准
- •1) To have completed the treatment specified in the central studies and to receive the first scheduled infusion of tocilizumab (MRA) of the WA18696 between 4 and 12 weeks after the last IV infusion of the central studies.
- •2) Appointed and willing to give written informed consent and to comply with the requirements of the study protocol.
- •3) MTX or other DMARDs will be allowed if they are maintained in a dose and stable route of administration since the last study drug administration in the central studies.
- •4) Oral corticosteroids and NSAIDs are allowed if the dose is stable since the last administration of the central studies drug.
- •5) If patients are taking MTX, they should agree to receive oral folate.
- •6) Women with potential fertility and men with women couples with potential fertility can participate in this study only if they use a reliable contraceptive method.
- •7) If it is a woman with potential fertility, the patient must have a negative urine pregnancy test at the beginning.
排除标准
- •1) A treatment with any agent under investigation since the last administration of the central studies drug.
- •2) Previous treatment with any cell depletion therapy, including agents under investigation.
- •3) Treatment with intravenous gammaglobulin, plasmapheresis or Prosorba ™ column since the last administration of the central studies drug.
- •4) Treatment with an anti-TNF or anti-IL-1 agent, or a costimulation modulator of T cells or any biological or participate in any research study since the last administration of the central studies drug.
- •5) Intramuscular or intraarticular parenteral corticosteroids, in the six weeks prior to the start of WA18696.
- •6) Immunization with a live / attenuated vaccine since the last drug administration of the central studies.
- •7) Any previous treatment with alkylating agents.
- •8) History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies.
- •9) Evidence of serious concomitant and uncontrolled cardiovascular, neurological, pulmonary, renal, hepatic, endocrine, immunological or gastrointestinal disease.
- •10) Bacterial, viral, fungal, mycobacterial or other known infections, active or with a history of recurrences, or any serious episode of infection that requires hospitalization or treatment with IV antibiotics within four weeks prior to initiation or oral antibiotics within two weeks before the initiation.
- •11) Evidence of active malignancy.
- •12) Patients whose AST or ALT values ≥ 3 times ULN, bilirubin> 2 times ULN or> 2.5 mg / dL.
研究者
相似试验
进行中（未招募）
不适用
ong-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in WA 17822MedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2005-002423-13-ITF.Hoffmann La Roche Ltd630
进行中（未招募）
不适用
ong-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in MRA core studies.MedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2005-002909-23-ITF. Hoffmann - La Roche Ltd2,420
进行中（未招募）
不适用
ong-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in MRA core studies.Rheumatoid arthritisEUCTR2005-002909-23-DEF Hoffmann-La Roche AG2,420
进行中（未招募）
1 期
ong-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in MRA core studies. - NARheumatoid arthritisEUCTR2005-002909-23-GBF Hoffmann La-Roche AG2,420
进行中（未招募）
不适用
ong-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in MRA core studies.Rheumatoid arthritisEUCTR2005-002909-23-NOF Hoffmann La-Roche AG2,420